Finance Watch: Aileron, Talaris, Frequency And The Search For Strategic Alternatives

Job Cuts Continue As Programs Fail, Cash Dwindles

Public Company Edition: Aileron, Talaris and Frequency said they will reduce expenses and seek options for maximizing shareholder returns under tough stock market conditions. However, CureVac and Supernus are among firms recently able to access new cash – $250m and $150m, respectively.

Finance Watch Public Company
• Source: Alamy

Strong clinical trial readouts can lead to surging stock prices and big follow-on public offerings (FOPOs), and in a less rocky market failed trial readouts mean that a biopharma company’s stock price may dip and a FOPO is not imminent. In the current volatile environment for publicly traded firms, failed studies are leading to significant cost cuts, massive layoffs and searches for strategic alternatives that may ultimately lead to dissolution of drug developers.

Aileron Therapeutics, Inc, Talaris Therapeutics, Inc. and Frequency Therapeutics Inc. are the latest companies to simultaneously disclose...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Financing

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.